SILO Silo Pharma: Price-to-Projected Revenue Ratio

Brandmark of Silo Pharma, Inc. (SILO)

Silo Pharma, Inc. (SILO) relies on investments as it lacks a stable cash flow. The projected P/S level on the GURU.Markets terminal chart visualizes this imbalance, where 87.10 reflects the latest metric value. While the nasal drug SPC-15 for PTSD offers growth prospects, strict DEA oversight and the risk of failed trials create significant barriers for the biotech firm.

Silo Pharma - SILO Market Cap to Expected Sales Ratio (period 04/28/2023 - 11/15/2026)

SILO (Silo Pharma, Inc.): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart silopharma.com|SILO - Average Forecast Price
- company stock capitalization data:
Market Value Silo Pharma|SILO - Company Buyout Price
- book value of equity indicators:
Book Value per Share Silo Pharma|SILO - Book Valuation of Business|Market Value to Book Value Ratio silopharma.com|SILO - Aggregate Company Assets
- company liabilities and liquidity data:
Debt to Equity Silo Pharma, Inc.|SILO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Silo Pharma|SILO - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Silo Pharma|SILO - Long-Term Liabilities|Company Short-Term Debts Silo Pharma|Quick Ratio silopharma.com
- financial results and valuation multiples details:
SILO - Net Profit|Expected Profit Silo Pharma, Inc.|SILO - Company Value to Net Income|Future Price to Earnings Silo Pharma Inc.|SILO - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Silo Pharma|SILO - Operating profit EBITDA|Net earnings per share for the last 12 months Silo Pharma|SILO - Earnings per share for the trailing year|Quarterly EPS earnings growth silopharma.com|SILO - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Silo Pharma, Inc.
- sales volume and revenue indicators:
SILO - Company Sales Volume|Projected Sales Volume silopharma.com|SILO - Market Cap to Revenue|Forward Price-to-Revenue Multiple Silo Pharma|SILO - Annual Revenue Growth (Last Twelve Months)
Summary company analysis:SILO (Silo Pharma)
Original product of Silo Pharma Inc.

Silo Pharma, Inc. (SILO) is developing innovative therapies for neurodegenerative pathologies based on psilocybin formulations. By analyzing the company's P/S expectations, an investor assesses market capitalization relative to projected revenue, which allows them to filter out speculative noise and determine a fair discount for future cash flows from clinical trials, thereby confirming the long-term fundamental stability of the business.

Direct competitors

Price-to-Projected Revenue Ratio alkermes.com ALKS|Avadel Pharma (AVDL) - Market Cap to Future Revenue Ratio|atai - Forward P/S Multiple|Projected Price to Revenue GH Research PLC (GHRS)|MNMD: Forward P/S Multiple|Market Cap to Future Revenue Ratio COMPASS Pathways PLC (CMPS)|Forward Price-to-Revenue Multiple LBRX|Bright Minds Biosciences Inc (DRUG) - Market Cap to Expected Sales Ratio|Forward P/S Multiple VNDA|Market Cap to Expected Sales Ratio Cybin Inc|Alto Neuroscience - Forward Price-to-Revenue Multiple|NRXP (NRx Pharmaceuticals, Inc.) - Future Price to Revenue|CING - Price-to-Projected Revenue Ratio|Forward Price to Sales CPHI (China Pharma Holdings, Inc.)|CMND: Forward P/S Multiple|Psyence Biomedical Ltd. - Forward Price to Sales|SPRC (SciSparc Ltd.) - Forward P/S Multiple|SEEL (Seelos Therapeutics, Inc.) - Price to Expected Revenue Ratio|Forward P/S Multiple VRPX|KRTX (Karuna) - Forward Price to Sales